Pardes to go public, says COVID-19 antiviral pill does not need booster
Pardes Biosciences on Tuesday said early human testing shows that its experimental COVID-19 antiviral pill works as a standalone treatment and announced plans to go public by merging with a special purpose acquisition company. If the drug, called PBI-0451, proves effective in later-stage testing, it could have an advantage over similar pills that need to [……
Read More
0
